Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Author(s): Andrew J. Armstrong, MD, ScM¹; Vinnie Y.T. Liu, MSc²; Ramprasaath R. Selvaraju, PhD²; Emmalyn Chen, PhD²; Jeffry P. Simko, MD, PhD³; Sandy DeVries, MA³; Oliver Sartor, MD⁴; Howard M. Sandler, MD⁵; Osama Mohamad, MD, PhD³; Huei-Chung Huang, MA²; Jacqueline Griffin, PhD²; Rikiya Yamashita, MD, PhD²; Andre Esteva, PhD²; Phuoc T. Tran, MD, PhD⁶; Daniel E. Spratt, MD⁷; John Hi Carson, MD⁸; Christopher Peters, MD⁹; Elizabeth Gore, MD^10,11; Steve P. Lee, MD, PhD¹²; Jedidiah M. Monson, MD¹³; Mark E. Augspurger, MD¹⁴; Ali El-Gayed, MD¹⁵; Joseph P. Rodgers, MS^16,17; Rana McKay, MD¹⁸; Todd Morgan, MD¹⁹; Felix Y. Feng, MD³; Paul L. Nguyen, MD²⁰;

Source: DOI: 10.1200/JCO.24.00365

Dr. Anjan Patel's Thoughts

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.

PURPOSE

Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration.

METHODS

A multimodal artificial intelligence (MMAI)???derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks.

RESULTS

In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed (P = .04) for DM, whereby MMAI biomarker???positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker???negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker???positive men and 0% in MMAI biomarker???negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001).

CONCLUSION

To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Author Affiliations

¹Duke University Medical Center, Durham, NC; ²Artera Inc, Los Altos, CA; ³University of California San Francisco, San Francisco, CA; ⁴Mayo Clinic, Rochester, MN; ⁵Cedars-Sinai Medical Center, Los Angeles, CA; ⁶University of Maryland, Baltimore, MD; ⁷Case Western Reserve University, Cleveland, OH; ⁸Saint John Regional Hospital, Saint John, New Brunswick, CA; ⁹Northeast Radiation Oncology Center, Dunmore, PA accrual for Regional Hospital of Scranton; ¹⁰Zablocki Veterans Administration Medical Center, Milwaukee, WI; ¹¹Medical College of Wisconsin, Milwaukee, WI, Accrual for Clarkson Hospital; ¹²Long Beach VA Healthcare System, Long Beach, CA; ¹³Saint Agnes Medical Center, Fresno, CA; ¹⁴Baptist Medical Center South, Jacksonville, FL; ¹⁵Saskatoon Cancer Centre, Saskatoon, SK; ¹⁶NRG Oncology Statistics and Data Management Center, Philadelphia, PA; ¹⁷American College of Radiology, Philadelphia, PA; ¹⁸University of California San Diego Moores Cancer Center, La Jolla, CA; ¹⁹University of Michigan, Ann Arbor, MI; ²⁰Brigham and Women's Hospital, Boston, MA

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Metformin did not significantly reduce the risk of disease progression compared with active surveillance in patients with low-risk prostate cancer.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

For our radiation oncology colleagues, the addition of PSMA-directed therapy prior to stereotactic body radiation therapy (SBRT) improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Two cycles of PSMA-directed therapy were administered before SBRT.

European Study of Prostate Cancer Screening — 23-Year Follow-up

A 13% reduction in mortality was observed in the screening group, with an improved harm-benefit ratio. For every 456 men screened, one prostate cancer death was prevented. It is an easy and inexpensive test, though concerns remain regarding unnecessary biopsies and overtreatment.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Pasritamig was administered to patients who had received a median of four prior lines of systemic therapy. It was well tolerated, with manageable adverse events, making it suitable for outpatient administration. The treatment showed a median radiographic progression-free survival of 7.85 months, and 14 out of 33 participants achieved a ≥50% reduction in baseline PSA levels. So, stay tuned.

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial

In patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease, the long-term update reveals 13-year outcomes. Treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT.